InvestorsHub Logo
Followers 56
Posts 19944
Boards Moderated 3
Alias Born 09/23/2009

Re: None

Wednesday, 08/23/2017 2:27:40 PM

Wednesday, August 23, 2017 2:27:40 PM

Post# of 9289
Mavericks & Mules



IMNP




Ticker IMNP [NASD]
Company Immune Pharmaceuticals, Inc.
Country USA
Industry Drug Manufacturers - Major
Market Cap 12.00M EPS (ttm) -7.76
P/E - EPS this Y 46.90%
Forward P/E - EPS next Y -
PEG - EPS past 5Y 44.60%
P/S - EPS next 5Y -
P/B 2.79 EPS Q/Q 87.80%
Dividend - Sales Q/Q -
Insider Own 34.78% Inst Own 5.20%
Insider Trans 0.00% Inst Trans 37.57%
Short Float 7.36% Earnings Sep 13/b
Analyst Recom 1.00 Target Price 60.00
Avg Volume 123.82K 52W Range 1.15 - 8.16
Aug-14-17 08:00AM Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer Business Wire
Aug-09-17 09:30AM CYTOVIA Inc, IMMUNE Pharmas Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent Business Wire
Aug-07-17 09:27AM CYTOVIA Inc., IMMUNE Pharmas Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML) Business Wire
Aug-04-17 10:16AM Immune Pharmaceuticals, Inc. Issues Letter to Shareholders Business Wire
Jul-19-17 09:32AM Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company Business Wire
Jul-13-17 07:30AM IMMUNE Pharmaceuticals Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1 Business Wire
Jul-11-17 01:45PM Cytovia Inc, Immune Pharmaceuticals Oncology Subsidiary, Enters into a Definitive Agreement with Pint Pharma for the Licensing and Commercialization of Ceplene® in Latin America Business Wire
Jul-05-17 08:30AM IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal PR Newswire
Jun-29-17 08:30AM Immune Pharmaceuticals' Oncology Subsidiary, Cytovia Inc. Provides Update to Proposed Pint Pharma Transaction: Substantial Agreement Reached on Material Terms of the Licensing and Commercialization of Ceplene® in Latin America PR Newswire
Jun-20-17 09:14AM Immune Pharmaceuticals announces initiation of enrollment in clinical trial with Ceplene®/ low-dose IL-2 in Chronic Myelomonocytic Leukemia (CMML) PR Newswire


Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis. The company's immuno-oncology pipeline includes Ceplene for the maintenance of remission in patients with acute myeloid leukemia, which is in Phase III clinical trial in the United States and has approved in European Union; Crolibulin, a small molecule vascular disrupting agents (VDA) and apoptosis inducer that is in Phase II clinical trial for the treatment of patients with solid tumors; Azixa, a Phase II microtubular destabilizer that functions as a VDA; NanomAbs, a preclinical stage antibody-drug conjugate platform that allows the targeted delivery of combinations of chemotherapeutics into cancer cells; and bispecific antibodies, which are in preclinical stage against immune-oncology targets. In addition, it develops AmiKet, a prescription topical analgesic cream that has completed II clinical trials for the treatment of neuropathic pain; and LidoPAIN, an adhesive-backed, lidocaine-based patch that is in Phase II clinical trial for the treatment of acute lower back pain. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

VERI




Ticker VERI [NASD]
Company Veritone, Inc.
Country USA
Industry Application Software
Market Cap 177.37M EPS (ttm) -4.77
P/E - EPS this Y -216.40%
Forward P/E - EPS next Y 60.90%
PEG - EPS past 5Y -
P/S 14.78 EPS next 5Y 20.00%
P/B 1.74 EPS Q/Q -264.50%
Dividend - Sales Q/Q 0.00%
Insider Own 51.90% Inst Own 8.60%
Insider Trans - Inst Trans -
Short Float 3.81% Earnings Aug 07/a
Analyst Recom 2.00 Target Price 17.00
Avg Volume 100.45K 52W Range 7.76 - 15.64
Aug-23-17 08:34AM Liolios Releases Presenting Company Roster for its 6th Annual Gateway Conference on September 6-7 in San Francisco GlobeNewswire
Aug-18-17 11:46PM [$$] Artificial Intelligence Gets a Lot Smarter Barrons.com
Aug-14-17 12:00PM Veritone Expands Relativity Integration with Advanced e-Discovery Language Translation Business Wire
Aug-07-17 04:05PM Veritone Reports Financial Results for the Second Quarter and First Six Months of 2017 Business Wire
Aug-03-17 11:43AM Veritone Conductor Produces Significant Accuracy Gains, Affirming that Orchestrated, Multi-Engine Cognition is the Future of Artificial Intelligence Business Wire
Aug-01-17 08:34AM Liolios 6th Annual Gateway Conference to Showcase 100 Companies at the Four Seasons San Francisco on September 6-7 GlobeNewswire
Jul-31-17 08:00AM Veritone to Present at the 37th Annual Canaccord Genuity Growth Conference on August 9, 2017 Business Wire
Jul-21-17 08:00AM Veritone Sets Second Quarter 2017 Earnings Call for Monday, August 7, 2017 at 4:30 p.m. EDT Business Wire
Jul-19-17 09:00AM LegalZoom Broadens Relationship with Veritone One to Include Local and National Advertising Campaigns Business Wire
Jul-13-17 09:00AM Veritone and B6A Collaborate to Deliver Unique Video Analytics and Insights with Artificial Intelligence Business Wire


Veritone, Inc., a cloud-based cognitive software company, develops a proprietary artificial intelligence platform for various markets in the United States and internationally. Its cloud-based open platform integrates and orchestrates an ecosystem of cognitive engines to reveal multivariate insights from various amounts of audio, video, and structured data; and incorporates proprietary technology to manage and integrate a range of AI processes to mimic human cognitive functions comprising perception, reasoning, prediction, and problem solving to transform unstructured data into structured data. The company offers media agency services, including media planning and strategy, media buying and placement, campaign messaging, clearance verification and attribution, and custom analytics to manage, deliver, optimize, verify, and quantify advertising campaigns and content distribution for various clients across multiple channels comprising broadcast radio, satellite audio, streaming audio, broadcast and cable television, digital video, and podcasting. It also provides Software-as-a-Service solutions for media owners and broadcasters to automatically index and organize audio and video content to search, discover, and analyze their media for programming and optimization; political organizations to analyze public and private media, conduct research, and provide access to previously inaccessible data; legal professionals to find the critical details of their cases by storing, organizing, and analyzing evidentiary media; and police and other government authorities to organize and gain insight from the large amount of audio, video, and structured data they accumulate on a daily basis, as well as offers solutions for other markets, including commercial security and retail. The company was formerly known as Veritone Delaware, Inc. and changed its name to Veritone, Inc. in July 2014. Veritone, Inc. was founded in 2014 and is headquartered in Newport Beach, California.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

ABEO





Ticker ABEO [NASD]
Company Abeona Therapeutics Inc.
Country USA
Industry Biotechnology
Market Cap 330.41M EPS (ttm) -0.60
P/E - EPS this Y -21.60%
Forward P/E - EPS next Y -18.30%
PEG - EPS past 5Y 43.10%
P/S 413.01 EPS next 5Y -
P/B 3.55 EPS Q/Q -0.50%
Dividend - Sales Q/Q 0.00%
Insider Own 47.70% Inst Own 38.40%
Insider Trans 0.00% Inst Trans 7.46%
Short Float 22.71% Earnings Aug 15
Analyst Recom 1.80 Target Price 19.40
Avg Volume 511.05K 52W Range 3.90 - 10.26

Aug-22-17 10:20PM Edited Transcript of ABEO earnings conference call or presentation 22-Aug-17 2:00pm GMT Thomson Reuters StreetEvents
Aug-17-17 09:15AM Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017 GlobeNewswire
Aug-16-17 09:39AM Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A GlobeNewswire
Aug-15-17 11:22PM Abeona Therapeutics reports 2Q loss Associated Press
Aug-15-17 08:25AM Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights GlobeNewswire
Jul-25-17 08:05AM Abeona Therapeutics Announces Appointment of Juan Ruiz as Chief Medical Officer GlobeNewswire
Jul-18-17 08:05AM Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa GlobeNewswire
Jul-10-17 01:49PM ETFs with exposure to Abeona Therapeutics, Inc. : July 10, 2017 Capital Cube
Jul-07-17 05:25PM Ahead of this year's MLB All-Star Game, here are 4 home r... CNBC Videos
Jul-06-17 08:15AM Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6% Zacks

Abeona Therapeutics Inc., a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

LZB





Ticker LZB [NYSE]
Company La-Z-Boy Incorporated
Country USA
Industry Home Furnishings & Fixtures
Market Cap 1.51B EPS (ttm) 1.73
P/E 18.06 EPS this Y 11.30%
Forward P/E 15.00 EPS next Y 12.29%
PEG 1.03 EPS past 5Y 2.20%
P/S 0.99 EPS next 5Y 17.50%
P/B 2.58 EPS Q/Q 26.10%
Dividend 1.41% Sales Q/Q -1.10%
Insider Own 1.70% Inst Own 91.20%
Insider Trans -14.33% Inst Trans 0.95%
Short Float 4.42% Earnings Aug 22/a
Analyst Recom 2.80 Target Price 34.00
Avg Volume 527.21K 52W Range 22.09 - 34.10

Aug-23-17 01:26PM Why Shares of La-Z-Boy Inc. Plunged Today Motley Fool
Aug-23-17 11:29AM La-Z-Boy: I Thought It Was Supposed to Recline! Barrons.com
Aug-23-17 09:40AM Stocks to Watch: Lowe's, Wal-Mart, Apple, Express, La-Z-Boy, Cree The Wall Street Journal
Aug-23-17 07:51AM Early movers: LOW, EXPR, CRM, GDDY, INTU, CREE, LZB & more CNBC
Aug-23-17 06:45AM La-Z-Boy to Host Fiscal 2018 First Quarter Earnings Results Conference Call and Webcast Live on Wednesday, August 23, 2017 ACCESSWIRE
Aug-22-17 09:28PM La-Z-Boy misses Street 1Q forecasts Associated Press
Aug-22-17 05:31PM After-hours buzz: WFC, CRM, CREE & more CNBC
Aug-22-17 04:39PM La-Z-Boy shares tank after earnings miss MarketWatch
Aug-22-17 04:39PM La-Z-Boy misses on top and bottom line CNBC Videos
Aug-22-17 04:15PM La-Z-Boy Reports Fiscal 2018 First-Quarter Results GlobeNewswire

La-Z-Boy Incorporated manufactures, markets, imports, exports, distributes, and retails upholstery furniture products, accessories, and casegoods furniture products in the United States, Canada, and internationally. It operates through Upholstery, Casegoods, and Retail segments. The Upholstery segment manufactures and imports upholstered furniture, such as recliners and motion furniture, sofas, loveseats, chairs, sectionals, modulars, ottomans, and sleeper sofas. This segment sells its products directly to La-Z-Boy Furniture Galleries stores, operators of Comfort Studios and England custom comfort center locations, dealers, and other independent retailers. The Casegoods segment imports, markets, and distributes casegoods/wood furniture, including bedroom sets, dining room sets, entertainment centers, and occasional pieces, as well as manufactures upholstered furniture. This segment sells its products to dealers, La-Z-Boy Furniture Galleries stores, and other independent retailers under the American Drew, Hammary, and Kincaid brands. The Retail segment sells upholstered furniture, casegoods, and other accessories to the end consumer through its retail network. This segment operates a network of 347 La-Z-Boy Furniture Galleries stores and 557 Comfort Studio locations, as well as in-store programs with 527 outlets in Kincaid and England. La-Z-Boy Incorporated also produces reclining chairs; and manufactures and distributes residential furniture. The company was formerly known as La-Z-Boy Chair Company and changed its name to La-Z-Boy Incorporated in 1996. La-Z-Boy Incorporated was founded in 1927 and is based in Monroe, Michigan.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

APOG



Ticker APOG [NASD]
Company Apogee Enterprises, Inc.
Country USA
Industry General Building Materials
Market Cap 1.40B EPS (ttm) 2.91
P/E 16.13 EPS this Y 33.50%
Forward P/E 11.25 EPS next Y 23.82%
PEG 1.61 EPS past 5Y 78.10%
P/S 1.23 EPS next 5Y 10.00%
P/B 2.81 EPS Q/Q -9.60%
Dividend 1.19% Sales Q/Q 9.80%
Insider Own 2.20% Inst Own 94.00%
Insider Trans -15.30% Inst Trans -1.75%
Short Float 15.98% Earnings Sep 21/b
Analyst Recom 1.70 Target Price 63.50
Avg Volume 226.17K 52W Range 39.88 - 61.00


Aug-23-17 10:03AM Caterpillar Hits 52-Week High on Upbeat Sales Growth Figures Zacks
Aug-23-17 06:30AM Apogee Updates FY18 Outlook for EFCO Acquisition Impact Business Wire
Aug-22-17 01:46PM Apogee Enterprises, Inc. : APOG-US: Dividend Analysis : July 10th, 2017 (record date) : By the numbers : August 22, 2017 Capital Cube
Aug-22-17 08:06AM See what the IHS Markit Score report has to say about Apogee Enterprises Inc. Markit
Aug-12-17 07:55AM Edited Transcript of APOG earnings conference call or presentation 22-Jun-17 1:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 03:44PM Middleby (MIDD) Q2 Earnings Beat by a Penny, Revenues Miss Zacks
Aug-09-17 10:01AM Caterpillar Scales 52-Week High: What's Driving the Stock? Zacks
Aug-08-17 03:57PM ETFs with exposure to Apogee Enterprises, Inc. : August 8, 2017 Capital Cube
Aug-01-17 10:20AM Xylem (XYL) Tops Q2 Earnings, Lifts 2017 EPS & Revenue View Zacks
Jul-31-17 10:22AM Bemis (BMI) Misses Q2 Earnings & Sales, Trims '17 Outlook Zacks


Apogee Enterprises, Inc. designs and develops glass products and services in the United States, Canada, and Brazil. The company operates through four segments: Architectural Glass, Architectural Framing Systems, Architectural Services, and Large-Scale Optical Technologies (LSO). The Architectural Glass segment fabricates coated and high-performance glass used in customized windows and wall systems comprising the outside skin of commercial, institutional, and multi-family residential buildings. The Architectural Framing Systems segment designs, engineers, fabricates, and finishes the aluminum frames used in customized aluminum and glass windows, curtain walls, storefronts, and entrance systems comprising the outside skin, as well as entrances of commercial, institutional, and multi-family residential buildings. The Architectural Services segment provides full-service installation of the walls of glass, windows, and other curtainwall products making up the outside skin of commercial and institutional buildings. The LSO segment manufactures value-added glass and acrylic products for the custom picture framing and display applications. The company's products and services are primarily used in commercial buildings, such as office towers, hotels, and retail centers; and institutional buildings, including education facilities and dormitories, health care facilities, and government buildings, as well as multi-family residential buildings. It markets its architectural products and services through direct sales force, independent sales representatives, and distributors to general contractors and glazing subcontractors, architects, and building owners; and value-added glass and acrylics through retail chains, picture framing shops, and independent distributors to museums, and public and private galleries and collections. Apogee Enterprises, Inc. was founded in 1949 and is headquartered in Minneapolis, Minnesota.

xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

EVLV




Ticker EVLV [NASD]
Company EVINE Live Inc.
Country USA
Industry Catalog & Mail Order Houses
Market Cap 58.75M EPS (ttm) -0.12
P/E - EPS this Y 32.10%
Forward P/E 11.44 EPS next Y -
PEG - EPS past 5Y 32.40%
P/S 0.09 EPS next 5Y 30.00%
P/B 0.84 EPS Q/Q 39.30%
Dividend - Sales Q/Q -6.40%
Insider Own 0.20% Inst Own 35.40%
Insider Trans 225.27% Inst Trans -13.62%
Short Float 0.59% Earnings Aug 23/b
Analyst Recom 2.00 Target Price 2.50
Avg Volume 241.14K 52W Range 0.89 - 2.40

Aug-23-17 11:06AM Evine Live reports 2Q loss Associated Press
Aug-23-17 06:45AM Investor Network: EVINE Live Inc. Class A to Host Earnings Call ACCESSWIRE
Aug-23-17 06:00AM Evine Live Inc. Reports Second Quarter 2017 Results GlobeNewswire
Aug-21-17 08:03AM Evine Brings Paula Deen, John OHurley and Akos The Solutionist to one of the Countrys Largest State Fairs GlobeNewswire
Aug-17-17 08:03AM Evine Live Inc. to Present at Upcoming Investor Conference GlobeNewswire
Aug-10-17 12:12PM Evine Rolls Out the Red Carpet to Host its Biggest Event of the Year All Star Gala GlobeNewswire
Aug-02-17 08:03AM Evine Live Inc. to Report Second Quarter 2017 Results on August 23, 2017 GlobeNewswire
Jul-13-17 03:59PM ETFs with exposure to EVINE Live, Inc. : July 13, 2017 Capital Cube
Jun-30-17 02:54PM ETFs with exposure to EVINE Live, Inc. : June 30, 2017 Capital Cube
Jun-27-17 09:31AM Evine Partners with World Class Product Inventor Akos Jankura to Launch Problem-Solving Product Line GlobeNewswire

EVINE Live Inc. operates as a multiplatform video commerce company in the United States. The company markets, sells, and distributes products to consumers through television, online, mobile, and social media in various merchandise categories, such as jewelry and watches, which include silver, gold, and gemstones to simulated diamonds; home and consumer electronics, which include home decor, bed and bath textiles, cookware, kitchen electrics, mattresses, tabletop accessories, and home furnishings; beauty products, including skincare, cosmetics, hair care, and bath and body products; and fashion and accessories, such as apparel, outerwear, intimates, handbags, accessories, and footwear. It has access to approximately 87 million cable and satellite television homes, as well as offers its products through online at evine.com. The company was formerly known as ValueVision Media, Inc. and changed its name to EVINE Live Inc. in November 2014. EVINE Live Inc. was founded in 1990 and is headquartered in Eden Prairie, Minnesota.

end

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.